Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Jundishapur Journal of Natural Pharmaceutical Products
  4. Articles

  5. Study the Mechanism of Antileishmanial Action of Xanthium strumarium Against Amastigotes Stages in Leishmania major: A Metabolomics Approach
  6. Scopus by Title (Ref)

Jundishapur Journal of Natural Pharmaceutical Products

The Official Journal of Ahvaz Jundishapur University of Medical Sciences

Home
Current IssueAccepted ManuscriptsAll IssuesIn PressSearch
Instructions
Journal InformationBoard & CommitteeIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormJoin JJNPP EditorialSupportContact Us
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. The therapeutic effect of larval saliva and hemolymph of Lucilia sericata on the treatment of Leishmania major lesion in BALB/c mice946

- Rahimi S. , et al.

2. Anti-Cancer Effect of Dorema Ammoniacum Gum by Targeting Metabolic Reprogramming by Regulating APC, P53, KRAS Gene Expression in HT-29 Human Colon Cancer Cells

- Ghodousi-Dehnavi E. , et al.

3. Antileishmanial Activity of Natural Diterpenoids: A Comprehensive Review

- Mirzania F. , et al.

HomeInstructionsAPC

Archives

  • Current Issue
  • Accepted Manuscripts
  • All Issues
  • In Press
  • Search

About Journal

  • Journal Information
  • Board & Committee
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Join JJNPP Editorial
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.